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ASSOCIATION BETWEEN GAIT SPEED WITH MORTALITY, CARDIOVASCULAR 1 
DISEASE AND CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS  2 
OF PROSPECTIVE COHORT STUDIES 3 
4 
2 
 
ABSTRACT 5 
Objectives: Slow gait speed may be associated with premature mortality, cardiovascular disease 6 
(CVD) and cancer, although a comprehensive meta-analysis is lacking. In this systematic review and 7 
meta-analysis, we explored potential associations between gait speed and mortality, incident CVD 8 
and cancer.  9 
Design: A systematic search in major databases was undertaken from inception until March 15th 2018 10 
for prospective cohort studies reporting data on gait speed and mortality, incident CVD and cancer.  11 
Setting and Participants: all available.  12 
Measures: The adjusted hazard ratios (HRs) and 95% confidence intervals (CIs), based on the model 13 
with the maximum number of covariates for each study between gait speed (categorized as decrease 14 
in 0.1 m/s) and mortality, incident CVD and cancer were meta-analysed with a random-effects model.   15 
Results: Among 7,026 papers, 44 articles corresponding to 48 independent cohorts were eligible. The 16 
studies followed-up a total of 101,945 participants (mean age 72.2 years; 55% women) for a median 17 
of 5.4 years. After adjusting for a median of 9 potential confounders and the presence of publication 18 
bias, each reduction of 0.1 m/s in gait speed was associated with a 14% increased risk of earlier 19 
mortality (45 studies; HR=1.12; 95% CI: 1.09-1.14; I2=90%) and 8% increased risk of CVD (13 20 
studies; HR=1.08; 95%CI: 1.03-1.13; I2=81%), but no relationship with cancer was observed 21 
(HR=1.00; 95%CI: 0.97-1.04; I2=15%).  22 
Conclusion/implications: Slow gait speed may be a predictor of mortality and CVD in older adults. 23 
Since gait speed is a quick and inexpensive measure to obtain our study suggests that it should be 24 
routinely used and may help identify people at risk of premature mortality and CVD.  25 
 26 
Key words: gait speed; mortality; cardiovascular disease; cancer; meta-analysis.  27 
28 
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INTRODUCTION 29 
The speed at which someone walks (gait speed) is an important indicator of a their functional status1. 30 
An increasing body of research suggests that, among older people, slow gait speed is an important 31 
predictor of a range of adverse health outcomes2-6. Since gait speed is a quick, inexpensive and 32 
reliable measure of functional capacity 7, it is widely recorded by physical therapists and other 33 
clinicians 8 to assess the functioning of healthy 1 or disease-affected 9 individuals.  34 
 35 
There is a particular interest in the relationship between gait speed and mortality. Cooper et al. 10 36 
reported that slow gait speed was associated with a significantly increased mortality risk in five 37 
studies. In a seminal paper, which was  not informed by a systematic review, data pooled from nine 38 
cohorts showed that faster gait speed was consistently associated with later survival in older adults 39 
11. More recently, a systematic review of the literature with meta-analysis 12 reported that slow gait 40 
speed was associated with a significant higher risk of death in 12,901 participants older than 65 years. 41 
Whilst these studies have advanced our knowledge regarding gait speed and mortality, one was 42 
limited to only older people 12, whilst another only adjusted for three potential confounders 10 a further 43 
was  not informed by a systematic review 11, thus offering an incomplete picture of the total evidence 44 
base on this topic.  45 
 46 
In addition, an increasing body of research highlighted the importance of slow gait speed as 47 
prognostic factor for other outcomes such as cancer 13 or cardiovascular disease (CVD) 14. Both CVD 48 
and cancer are the most important (and partially preventable) causes of death in industrialized 49 
countries15. Thus, to understand if slow gait speed is associated with higher incidence of CVD and 50 
cancer could be of interest. To the best of our knowledge, only one systematic review and meta-51 
analysis has reported data regarding slow gait speed and CVD, but these findings were limited to 52 
patients affected by peripheral artery disease at baseline 16.  In addition, no data are available 53 
regarding the association between slow gait speed and incident cancer, but it could be of importance 54 
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to know if gait speed may provide additional prognostic information to improve life expectancy 55 
estimation and management decisions in cancer patients.   56 
 57 
Given this background, we aimed to investigate the association between slow gait speed and 58 
mortality, taking in account different population settings and conditions. Moreover, we aimed to 59 
investigate the potential association between gait speed and incident CVD and cancer.  60 
61 
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METHODS 62 
This systematic review was conducted according to the Strengthening the Reporting of Observational 63 
Studies in Epidemiology [STROBE] criteria 17 and the recommendations in the Preferred Reporting 64 
Items for Systematic Reviews and Meta-Analyses [PRISMA] statement. 18  The protocol of this 65 
systematic review and meta-analysis pre-conceived, but not published and is  available upon request 66 
to the corresponding author.  67 
 68 
Search strategy 69 
The published literature was searched using key words for the concepts of gait speed, risk, 70 
mortality/death/survival, CVD, and cancer until March 15th, 2018. The search strategies were 71 
established using a combination of standardized terms and key words. The search strategy used in 72 
PubMed was reported in Supplementary Table 1 and run in the other databases (Embase, PsycINFO 73 
and the Cochrane Library). Two investigators (NV, BS) independently conducted an electronic 74 
literature search and inconsistencies were resolved by consensus with a third author (SM).  75 
 76 
References of articles included in the analysis and of others relevant to the topic were hand-searched 77 
to identify additional, potentially relevant publications. Conference abstracts were also considered.  78 
If we encountered a conference abstract with potentially relevant data, we contacted the authors up 79 
to four times over a month period to enable inclusion and acquire the variables of interest.   80 
 81 
Study selection 82 
We only considered studies that: a) had a prospective design; b) reported information regarding gait 83 
speed measured by trained health personnel; c) reported data on incident mortality, CVD, or cancer 84 
determined via medical records, hospital records, confirmed physician-based diagnosis or via self-85 
report or confirmed by relatives in the case of death).  86 
 87 
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Studies were excluded if they: a) did not report data regarding gait speed or the outcomes of interest; 88 
b) reported data regarding transitions in gait speed over a follow-up period and outcomes of interest; 89 
c) reported gait speed as self-reported information; d) reported data as odds ratios, OR (in this case, 90 
the authors were contacted at least 4 times in a month to obtain the corresponding hazard ratios, HRs).  91 
 92 
Data extraction 93 
To be included in the quantitative synthesis, studies had to provide data on risk estimates for death, 94 
any type of CVD or for specific CVD or cancer as HRs, together with precision estimates (95% 95 
confidence interval [95%CI]). Two authors (NV, EC) independently recorded data extracted from the 96 
selected studies into a standardized Microsoft Excel spreadsheet. Any disagreement was resolved by 97 
consensus with a third author (BS).  98 
 99 
The following information was extracted: i) study characteristics; ii) study setting (e.g., community); 100 
iii) main condition (e.g. frailty, general, CVD , etc.); iv) demographic characteristics of the whole 101 
population (percentage of women and mean age); v) type and number of adjustments used in the 102 
multivariate analyses; vi) duration of follow-up; vii) distance (in meters) over which gait speed was 103 
recorded. When two or more studies represented the same cohort, the largest study was included.   104 
 105 
Outcomes 106 
The primary outcome was all-cause mortality analyzed through the adjusted HRs from the model 107 
with the maximum number of covariates in each study. This outcome was also analyzed according to 108 
settings and any medical conditions present at baseline. The incidence of composite CVD (fatal or 109 
non-fatal events) and cancer were considered as secondary outcomes.  110 
 111 
Assessment of study quality 112 
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The Newcastle-Ottawa Scale (NOS) 19,20 was used to assess study quality. The NOS assigns a 113 
maximum of 9 points based on three quality parameters: selection, comparability, and outcome, with 114 
a cut-off of <5 being indicative of high risk of bias 19. NOS scores were initially assessed by two 115 
investigators (NV, BS), and discrepancies were addressed by a joint re-evaluation of the article with 116 
a third author (EC).  117 
 118 
Statistical analysis 119 
Analyses were performed by one investigator (NV) and checked by another researcher (EC) using 120 
Comprehensive Meta-Analysis (CMA) 2 (http://www.meta-analysis.com).   121 
 122 
Pooled risks of all study endpoints (all-cause mortality and incident CVD and cancer) were computed 123 
for per -0.1 m/s reduction in gait speed using fully-adjusted HRs. If these estimates were not reported 124 
in the original studies, they were calculated as the inverse variance-weighted mean of the logarithm 125 
of HR.21  126 
 127 
The random effects model was used to account for anticipated between-study heterogeneity 22. This 128 
was assessed using the Chi-squared and I-squared statistics, assuming that a p<0.10 for the former 129 
and a value ≥50% for the latter were indications of significant heterogeneity 23. Whenever significant 130 
heterogeneity existed and ≥4 studies were available, a meta-regression analysis was performed 131 
examining the following pre-specified moderators: setting (community-dwelling vs. others), 132 
condition (general population, presence of cancer/CVD or other medical conditions at baseline), type 133 
of ascertainment (categorized as death certificates, medical/administrative data, phone calls, not 134 
reported), mean age (categorized as less or more than 75 years, median value), percentage of females 135 
(by the median value, 55%), number of covariates (by the median value, i.e.=9), distance walked in 136 
the gait speed assessment (< vs. > 4 meters), and quality of the studies (by the median value, i.e.=9). 137 
For incident CVD we also stratified analysis for fatal or non-fatal events.   138 
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 139 
Publication bias was assessed by visual inspection of funnel plots and using the Egger bias test 24. 140 
When ≥3 studies were available, we used the Duval and Tweedie non-parametric trim-and-fill method 141 
to account for potential publication bias. Based on the assumption that the effect sizes of all the studies 142 
are normally distributed around the center of a funnel plot, in the event of asymmetries, this procedure 143 
adjusts for the potential effect of unpublished (trimmed) studies 25.  144 
145 
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RESULTS 146 
The search identified 7,026 non-duplicated, potentially eligible studies. After excluding 6,927 papers 147 
on the grounds of a review of their titles and abstracts, 99 full-text articles were examined, and 44 148 
articles 11,26-69 were finally included in our meta-analysis (eFigure 1), with one paper 11 giving 149 
information for 5 cohorts in our analyses. Thus, 48 cohorts were included in the meta-analysis.   150 
 151 
Study and patient characteristics 152 
The 48 cohorts followed-up a total of 101,945 participants over a median of 5.4 years (range: 0.5-153 
13.5) (eTable 1). These participants were on average 72.2 years old (95%CI: 59.1-85.0) and mainly 154 
women (=55 %; 95%CI: 52.0-55.6%). All the studies reported data regarding mortality, except three 155 
studies which reported data only on incident CVD 26,42,57, and one only on incident cancer 47.   156 
 157 
The studies were mainly conducted in Europe (n=22). The most common setting was the community 158 
(n=35). The study samples were primarily from general population (n=26), followed by specific 159 
clinical conditions (e.g. dementia, heart failure, cancer) (n=22). The studies mainly investigated gait 160 
speed over 4 m (n=21). The quality of the studies was generally high, as shown by the median value 161 
of the NOS scale (median=9), with only six studies at high risk of bias (NOS < 5) (eTable 1).  162 
 163 
All-cause Mortality 164 
Figure 1 shows the association between a reduction of 0.1 m/s in gait speed and mortality including 165 
45 cohorts with 71,308 participants and 19,294 deaths (=27.1% of the baseline population).  Death 166 
was ascertained through medical/administrative data in 23 studies and through death certificates in 167 
five studies.  168 
 169 
After adjusting for a median of 9 potential confounders (range: 0-22) and pooling data from 45 170 
cohorts, a reduction of 0.1 m/s in gait speed was associated with an increased risk of mortality of 14% 171 
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(HR=1.14; 95% CI: 1.11-1.17; p<0.0001; I2=90%). The Egger’s test suggested a presence of 172 
significant publication bias (=2.21±0.60; p=0.0007). The recalculated HR was 1.12 (95%CI: 1.09-173 
1.14), after trimming 9 studies to the left of the mean. The fail-safe number was 7,646, indicating a 174 
large number of negative studies would be required to nullify the finding.  175 
 176 
Table 1 reports the association between gait speed and mortality stratified by some possible 177 
confounders. In the studies among community-dwellers the association between a reduction in 0.1 178 
m/s and mortality (HR=1.12; 95%CI: 1.09-1.15; p<0.0001; I2=92%; 31 studies) was lower than those 179 
conducted in other settings (i.e. outpatients, nursing home, hospital) (HR=1.19; 95%CI: 1.14-1.24; 180 
p<0.0001; I2=53%; 14 studies) (Table 1). There was some indication of publication bias in settings 181 
other than community (Egger’s test=2.23±0.36; p=0.0005). After trimming 6 studies to the left of the 182 
mean, the adjusted HR was 1.21 (95%CI: 1.10-1.32). The fail-safe number was 2,219 for studies 183 
conducted among community dwellers and 507 in the other settings investigated.  184 
 185 
When stratified by conditions, a reduction of 0.1 m/s in gait speed was associated with a higher 186 
mortality rate ranging from a HR=1.10 (95%CI: 1.01-1.20; p=0.03; I2=87%; 3 studies) in people 187 
affected by cancer to a HR=1.15 (95%CI: 1.11-1.17; p<0.0001; I2=71%; 23 studies) in the general 188 
population (Table 1). Studies conducted in the general population did not show evidence of any 189 
publication bias (Egger’s test=0.08±0.63; p=0.90) and the fail-safe number for this outcome was 190 
1897. 191 
 192 
The meta-regression showed that none of the confounders (mean age, percentage of females, type of 193 
ascertainment, distance walked, number of covariates or quality) affected our results (Table 1).  194 
 195 
Cardiovascular diseases 196 
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The association between decreasing gait speed and incident CVD is reported in Figure 2. Of the 13 197 
studies included, 8 reported CVD related mortality as an outcome 27,41,43,57,62-65, two a composite 198 
outcome 31,44, one the onset of coronary heart disease 26, one stroke 42 and one hospitalization for heart 199 
failure 38.  200 
After adjusting for a median of 14 potential confounders (range: 9-22), each reduction of 0.1 m/s in 201 
gait speed was associated with a higher risk of fatal or non-fatal (composite) CVD by 13% (HR=1.13; 202 
95%CI: 1.08-1.18; p<0.0001; I2=81%). There was some evidence of publication bias (Egger’s test: 203 
2.92±0.76; p=0.003) and, after trimming 4 studies to the left of the mean, the recalculated HR was 204 
1.08 (95%CI: 1.03-1.13). The fail-safe number for this outcome was 371.    205 
 206 
Among the moderators for the incidence of CVD investigated, studies using CVD related death as 207 
the outcome reported a HR of 1.19 (95%CI: 1.10-1.29), even if no moderator (setting, main condition, 208 
mean age, quality, number of covariates, type of outcome) explained any heterogeneity of our 209 
findings.  210 
 211 
Cancer 212 
Four studies reported data regarding a reduction in gait speed and incidence of cancer (three regarding 213 
overall cancer mortality 41,62,64 and one regarding incident breast cancer 47) including a total of 20,717 214 
participants and 1,087 events (=5.2%). After adjusting for a median of 17 potential confounders 215 
(range: 13-21), each reduction in 0.1 m/s in gait speed was not associated with the risk of cancer 216 
(HR=1.00; 95%CI: 0.97-1.04; p=0.97; I2=15%; Figure 2). For this outcome, publication bias was not 217 
evident (Egger’s test: 1.53±0.88; p=0.22).  218 
Similar findings were evident for cancer related mortality (3 studies; HR=1.02; 95%CI: 0.95-1.09; 219 
I2=35%).  220 
221 
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DISCUSSION 222 
In this meta-analysis, including 48 cohorts and more than 100,000 participants, we found that slow 223 
gait speed was associated with an increased risk of earlier mortality, incident CVD, whilst we did not 224 
observe a relationship between gait speed and incident cancer. After adjusting for multiple 225 
confounders, the risk-effect associated with a reduction of 0.1 m/s in gait speed was consistent with 226 
death and the onset of CVD, which was present after adjusting for publication bias and our additional 227 
analysis indicated that a high number of studies would be required to nullify the effects (particularly 228 
for death).   229 
 230 
Two previous meta analyses have previously reported a significant association between slow gait 231 
speed and mortality 10,11. Our findings are substantially in agreement with these two papers, but our 232 
study added many other studies published in recent years and is the largest meta-analysis on this topic 233 
containing over 100,000 people. In addition, our meta-analysis included all people independently 234 
from their baseline conditions and after a systematic review of the literature. The significant overall 235 
effects of our meta-analysis are supported by consistent findings of individual studies since we found 236 
a higher risk of death across 44/48 (=92%) studies.  When compared to the previous literature 237 
regarding gait speed and mortality, we would like to report several novel/important points from our 238 
meta-analysis. First, a previous large systematic review and meta-analysis was limited to only older 239 
people 12 and other outcomes of great epidemiological and clinical interest, such as cancer or CVD, 240 
were not considered. Another meta-analysis regarding gait speed and mortality included only three 241 
potential confounders 10, whilst, a seminal meta-analysis regarding gait speed and mortality, was not 242 
supported by a systematic review of the literature 11, potentially introducing a bias. Finally, we have 243 
for the first time conducted numerous subgroup analyses such as according to the setting, population, 244 
mean age and percentage of females to better explain the findings and provide a more meaningful, 245 
targeted clinical message which was previously not available. Unfortunately, despite the large number 246 
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of stratification, no moderator was able to explain the heterogeneity of our findings suggesting that 247 
other factors could influence our results.   248 
 249 
The reason why slow gait speed is associated with premature death is unclear but may be explained 250 
through several pathways. First, a common contributor to slow gait speed is the presence of other co-251 
morbidities (e.g. diabetes, osteoarthritis) which have also been associated with premature mortality 252 
15,70. However, the original papers included in our pooled analyses were adjusted for many of these 253 
confounders. Second, slow gait speed is commonly associated with endocrine dysfunction (such as 254 
low testosterone levels) 71, inflammation 72 and oxidative stress 73 and all these factors are associated 255 
with higher risk of death 74-76. Next to this, gait speed may indicate difficulties with activities of daily 256 
living and engaging in physical activity, restrictions within each of these have been associated with 257 
increased risk of earlier death 77. Finally, as supported by a recent meta-analysis on function and 258 
mortality 78, gait speed is a powerful predictor of death, being able to early capture the multisystemic 259 
impairment associated with aging and multimorbidity. Therefore, gait speed might be an indicator of 260 
functional reserve and resilience.  261 
 262 
A similar argument can be proposed for the relationship between slow gait and CVD.  Higher 263 
inflammatory and oxidative stress levels are known risk factors for the onset of CVD 79, and people 264 
with  endocrine abnormalities often have slow gait speed 80. Some researchers have reported that slow 265 
gait speed is associated also with sub-clinical atherosclerotic lesions81. This may explain the higher 266 
incidence of CVD in people with slow gait speed. Moreover, the results of our work are in agreement 267 
with recent evidence highlighting frailty as a potential CVD risk factor 82 and suggesting that frailty, 268 
sarcopenia, malnutrition and disability are inter-connected domains83.  However, a possible limitation 269 
of the studies investigating fatal CVD events as outcomes is that they did not adjust for the presence 270 
at baseline of previous CVD. Even if the adjustment for other factors is probably sufficient (minimum 271 
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9), we recommend that other studies using people free from CVD or at least adjusting for this relevant 272 
factor at baseline are required.   273 
 274 
On the contrary, we did not find any association between slow gait speed and incident cancer. Whilst 275 
it may be true that there is no relationship between gait speed and cancer incidence, it is also possible 276 
that we failed to identify a relationship as due to inadequate statistical power, as this analysis was 277 
limited to four studies and only 5.2% of the baseline population developed cancer during the follow-278 
up period – raising the possibility of type II error. Similarly to our findings Wu et al. found, in a large 279 
meta-analysis in community-dwellers, that low handgrip strength is associated with a higher 280 
incidence of death and CVD, but not cancer 84. Since cancer is increasing worldwide 85, to elucidate 281 
whether slow gait speed is associated with higher incidence of cancer is of importance and 282 
consequently other studies with larger populations and longer follow-ups are needed to clarify this 283 
issue.   284 
 285 
Whilst our paper represents a comprehensive meta-analysis of the relationship between gait speed 286 
and these outcomes, it should be interpreted within its limitations. First, gait speed was assessed 287 
differently across the studies included. Second, as mentioned before, we were not able to explain the 288 
high level of heterogeneity found regarding mortality and CVD. Moreover, some outcomes were 289 
affected by publication bias.  Whilst we attempted to reduce this by attempting to include conference 290 
abstracts and we adjusted our results for publication bias using the trim and fill analysis, we cannot 291 
exclude the possibility that studies reporting negative or null findings may not have been published 292 
and could influence our findings. Third, people not able to walk were not considered in these cohort 293 
studies, but it is widely known that are at higher risk of mortality. However, this source of bias cannot 294 
be addressed. Finally, we had only four studies eligible for cancer and other works are needed for this 295 
outcome.  296 
 297 
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In conclusion, slow gait speed is a significant predictor of mortality and of the onset of CVD, whilst 298 
no significant association was found for cancer. Since gait speed is a quick and inexpensive measure 299 
to obtain, also in older and vulnerable people, our work suggests that it should be routinely used. 300 
Future studies on the association between slow gait speed and cancer are warranted. 301 
302 
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FIGURE LEGEND 541 
 542 
Figure 1. Meta-analysis of pooled hazard ratios (HRs) of gait speed and mortality.  543 
 544 
 545 
Figure 2. Meta-analysis of pooled hazard ratios (HRs) of gait speed and incident 546 
cardiovascular disease and incident cancer. 547 
